Back

NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology and therapy Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

3 More presentations in this session

Presentation thumbnail
Age- and sex-specific association between clonal hematopoiesis of indeterminate potential and pulmonary hypertension
Doctor G. Sun (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Variability in echocardiographic surveillance for cardiotoxicity in HER2+ versus HER2- breast cancer: a SEER-medicare analysis
Associate Professor J. Strom (Boston, US)
Abstract Slides Video
Presentation thumbnail
The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study
Associate Professor B. Polegato (Botucatu, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology and therapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences
thumbnail
Congress Presentation
The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources